Published in J Diabetes Res on December 06, 2015
Strict glucose control and artificial regulation of the NO-ADMA-DDAH system in order to prevent endothelial dysfunction. J Physiol (2016) 0.75
Vascular Aging: Implications for Cardiovascular Disease and Therapy. Transl Med (Sunnyvale) (2016) 0.75
Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest (2001) 23.21
Nitric oxide synthases in mammals. Biochem J (1994) 6.50
Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest (1996) 4.98
Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) (2012) 4.04
Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab (2009) 3.98
Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation (2013) 3.45
Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA (2002) 3.20
Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J Am Soc Nephrol (2007) 3.08
Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation (2001) 2.64
Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation (2001) 2.59
Impaired insulin signaling in endothelial cells reduces insulin-induced glucose uptake by skeletal muscle. Cell Metab (2011) 2.42
Inducible nitric oxide synthase in human diseases. Clin Exp Immunol (1998) 2.21
Endothelial nitric oxide synthase uncoupling impairs endothelial progenitor cell mobilization and function in diabetes. Diabetes (2007) 2.12
Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. Am J Physiol Heart Circ Physiol (2007) 2.05
Neuronal nitric oxide synthase: structure, subcellular localization, regulation, and clinical implications. Nitric Oxide (2009) 2.00
Deficiency of endothelial nitric-oxide synthase confers susceptibility to diabetic nephropathy in nephropathy-resistant inbred mice. Am J Pathol (2007) 1.95
Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence. Circulation (2003) 1.84
Plasma asymmetric dimethylarginine predicts death and major adverse cardiovascular events in individuals referred for coronary angiography. Int J Cardiol (2011) 1.73
Soluble RAGE in type 2 diabetes: association with oxidative stress. Free Radic Biol Med (2007) 1.67
Active participation of endothelial cells in inflammation. J Leukoc Biol (2005) 1.61
Mice with gene disruption of both endothelial and neuronal nitric oxide synthase exhibit insulin resistance. Diabetes (2000) 1.59
Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol (2001) 1.53
Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab (2014) 1.53
Vascular complications of diabetes: mechanisms of injury and protective factors. Cell Metab (2013) 1.51
Insulin stimulation of glucose uptake in skeletal muscles and adipose tissues in vivo is NO dependent. Am J Physiol (1998) 1.32
Isoform-specific regulation by N(G),N(G)-dimethylarginine dimethylaminohydrolase of rat serum asymmetric dimethylarginine and vascular endothelium-derived relaxing factor/NO. Circ Res (2007) 1.29
Physiology of the endothelium. Br J Anaesth (2004) 1.25
The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis. Nat Rev Drug Discov (2011) 1.21
Dimethylarginine dimethylaminohydrolase-1 is the critical enzyme for degrading the cardiovascular risk factor asymmetrical dimethylarginine. Arterioscler Thromb Vasc Biol (2011) 1.19
Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease. Arterioscler Thromb Vasc Biol (2006) 1.18
Dimethylarginine dimethylaminohydrolase overexpression enhances insulin sensitivity. Arterioscler Thromb Vasc Biol (2008) 1.16
Endothelium: a distributed organ of diverse capabilities. Ann N Y Acad Sci (1982) 1.10
Vascular endothelial-specific dimethylarginine dimethylaminohydrolase-1-deficient mice reveal that vascular endothelium plays an important role in removing asymmetric dimethylarginine. Circulation (2009) 1.10
Long-term oral L-arginine administration improves peripheral and hepatic insulin sensitivity in type 2 diabetic patients. Diabetes Care (2001) 1.10
Asymmetric dimethylarginine is closely associated with the development and progression of nephropathy in patients with type 2 diabetes. Nephrol Dial Transplant (2009) 1.09
Asymmetric dimethylarginine as a mediator of vascular dysfunction and a marker of cardiovascular disease and mortality: an intriguing interaction with diabetes mellitus. Diab Vasc Dis Res (2010) 1.05
Activation of L-arginine transport (system y+) and nitric oxide synthase by elevated glucose and insulin in human endothelial cells. J Physiol (1996) 1.03
Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats. Hypertens Res (2005) 1.02
Salt loading on plasma asymmetrical dimethylarginine and the protective role of potassium supplement in normotensive salt-sensitive asians. Hypertension (2006) 1.02
Insulin impairs endothelium-dependent vasodilation independent of insulin sensitivity or lipid profile. Am J Physiol Heart Circ Physiol (2003) 1.01
Hepatic glutathione and nitric oxide are critical for hepatic insulin-sensitizing substance action. Am J Physiol Gastrointest Liver Physiol (2002) 1.00
Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus. Vasc Med (2007) 0.98
High glucose inhibits insulin-stimulated nitric oxide production without reducing endothelial nitric-oxide synthase Ser1177 phosphorylation in human aortic endothelial cells. J Biol Chem (2003) 0.97
Plasma concentrations of asymmetric-dimethyl-arginine in type 2 diabetes associate with glycemic control and glomerular filtration rate but not with risk factors of vasculopathy. Metabolism (2003) 0.97
The endothelium: a new target for therapy. Vasc Med (2000) 0.96
Sulfonylurea use and incident cardiovascular disease among patients with type 2 diabetes: prospective cohort study among women. Diabetes Care (2014) 0.95
Dimethylarginine dimethylaminohydrolase overexpression ameliorates atherosclerosis in apolipoprotein E-deficient mice by lowering asymmetric dimethylarginine. Am J Pathol (2010) 0.93
Skeletal muscle nitric oxide signaling and exercise: a focus on glucose metabolism. Am J Physiol Endocrinol Metab (2012) 0.92
Asymmetric dimethylarginine induces endothelial nitric-oxide synthase mitochondrial redistribution through the nitration-mediated activation of Akt1. J Biol Chem (2012) 0.92
Blockade of hepatic nitric oxide synthase causes insulin resistance. Am J Physiol (1999) 0.91
Dietary nitrate, nitric oxide, and restenosis. J Clin Invest (2011) 0.91
Rosiglitazone prevents free fatty acid-induced vascular endothelial dysfunction. J Clin Endocrinol Metab (2007) 0.90
Link between insulin resistance and hypertension: What is the evidence from evolutionary biology? Diabetol Metab Syndr (2014) 0.88
Role of endothelial nitric oxide synthase in diabetic nephropathy: lessons from diabetic eNOS knockout mice. J Diabetes Res (2014) 0.88
Development of a dimethylarginine dimethylaminohydrolase (DDAH) assay for high-throughput chemical screening. J Biomol Screen (2012) 0.86
Tetrahydrobiopterin has a glucose-lowering effect by suppressing hepatic gluconeogenesis in an endothelial nitric oxide synthase-dependent manner in diabetic mice. Diabetes (2013) 0.85
Regulation of obesity and insulin resistance by nitric oxide. Free Radic Biol Med (2014) 0.85
FXR agonist INT-747 upregulates DDAH expression and enhances insulin sensitivity in high-salt fed Dahl rats. PLoS One (2013) 0.83
A novel and potent inhibitor of dimethylarginine dimethylaminohydrolase: a modulator of cardiovascular nitric oxide. J Pharmacol Exp Ther (2013) 0.81
The hydrolase DDAH2 enhances pancreatic insulin secretion by transcriptional regulation of secretagogin through a Sirt1-dependent mechanism in mice. FASEB J (2013) 0.80
Elevated tissue factor expression contributes to exacerbated diabetic nephropathy in mice lacking eNOS fed a high fat diet. J Thromb Haemost (2010) 0.80
Asymmetric dimethylarginine and long-term adverse cardiovascular events in patients with type 2 diabetes: relation with the glycemic control. Cardiovasc Diabetol (2014) 0.79
Antidiabetic drug metformin is effective on the metabolism of asymmetric dimethylarginine in experimental liver injury. Diabetes Res Clin Pract (2014) 0.79
AMP-activated protein kinase regulates L-arginine mediated cellular responses. Nutr Metab (Lond) (2013) 0.79
Metformin reduces asymmetric dimethylarginine and prevents hypertension in spontaneously hypertensive rats. Transl Res (2014) 0.78
The effect of rosiglitazone on asymmetric dimethylarginine (ADMA) in critically ill patients. Pharmacol Res (2009) 0.77
Dimethylarginine-dimethylaminohydrolase-2 (DDAH-2) does not metabolize methylarginines. Chembiochem (2012) 0.76
Spontaneous myocardial infarction and nitric oxide synthase. Trends Cardiovasc Med (2008) 0.76
The association of adipose-derived dimethylarginine dimethylaminohydrolase-2 with insulin sensitivity in experimental type 2 diabetes mellitus. Acta Biochim Biophys Sin (Shanghai) (2013) 0.76